Detailled Information

Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, Black CM, Czirjak L, Nielsen H, Vlachoyiannopoulos PG. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003 Sep;62(9):901-3.

Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. 

Assessment of the predictive value for short-term disease severity accrual of the EUSTAR-AI, as compared with those of the EScSG-AI and of known adverse prognostic factors.

Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis, Rheumatology. 

Evaluation of the construct validity of the European Scleroderma Study Group (EScSG) activity index and modifications proposal.

An Update of Outcome Measures in Systemic Sclerosis. Arthritis Care & Research. 

Review  to update various outcome measurements in SSc that have been used in clinical trials and/or have testing characteristics published, such as reliability and sensitivity to change.

The EScSG-AI is an SSc-specific measure for all patients with SSc. It contains the following 10 variables: total skin score, scleredema, digital necrosis, arthritis, erythrocyte sedimentation rate, reduced carbon monoxide transfer factor, hypocomplementemia, and patient-reported skin, vascular, and cardiopulmonary changes.

The index defines disease activity for SSc

Each variable from 0.5 to 2. Total score ranges from 0 to 10.

The EUSTAR-AI was developed from the charts of 97 patients in the European Scleroderma Trials and Research database and validated in 60 patients recruited from the same database.